Axsome Q2 product revenue $150M (+72% YoY); AUVELITY sales $119.6M

Axsome Therapeutics, Inc.

2025-Q2 EPS reported -$2.18 revenue$271,505,000

Total net product revenue $150.0M, up 72% YoY and 24% sequentially.
AUVELITY net sales $119.6M (+84% YoY); ~192k prescriptions written in Q2.
Net loss narrowed to $48.0M ($0.97/share) from $79.3M ($1.67/share) in Q2 2024.
Cash $303.0M; management says sufficient to fund operations into cash flow positivity.
Pipeline: sNDA for AXS-05 in Alzheimer's agitation on track for Q3 2025; NDA for AXS-12 in narcolepsy expected Q4 2025.

item 2.02item 8.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.